References of "COLLIGNON, Joëlle"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPourquoi les traitements de radiothérapie adjuvante pour cancer du sein ne comptent-ils plus autant de séances ?
Coucke, Philippe ULg; Jansen, Nicolas ULg; Collignon, Joëlle ULg et al

in Revue Médicale de Liège (2010), 65(1), 10-14

La radiothérapie adjuvante postopératoire pour cancer du sein compte habituellement vingt-cinq séances de radiothérapie auxquelles on ajoute une surimpression centrée sur le lit tumoral. Dans le contexte ... [more ▼]

La radiothérapie adjuvante postopératoire pour cancer du sein compte habituellement vingt-cinq séances de radiothérapie auxquelles on ajoute une surimpression centrée sur le lit tumoral. Dans le contexte d’une augmentation progressive et continue de la charge de travail et afin de réduire les contraintes humaines et techniques, une radiothérapie plus courte est aujourd’hui utilisée. Ces schémas hypo-fractionnés sont validés par des essais randomisés et publiés. Sur la base de ces publications, un nouvel arbre décisionnel a été établi qui permet d’obtenir des résultats équivalents en contrôle local tout en gardant un taux de complications comparable, voire même inférieur au schéma classique [less ▲]

Detailed reference viewed: 104 (8 ULg)
Full Text
Peer Reviewed
See detailL'observance au traitement de longue durée : le cas particulier de l'hormonothérapie adjuvante du cancer du sein
Bleret, Valerie ULg; Collignon, Joëlle ULg; Coucke, Philippe ULg et al

in Revue Médicale de Liège (2010), 65(5-6), 405-408

L'objectif de l'hormonothérapie adjuvante dans le cancer du sein est d'atteindre en pratique quotidiennee, une efficacité comparable à celle obtenue au cours des études cliniques. Malgré l'efficacité ... [more ▼]

L'objectif de l'hormonothérapie adjuvante dans le cancer du sein est d'atteindre en pratique quotidiennee, une efficacité comparable à celle obtenue au cours des études cliniques. Malgré l'efficacité démontrée de l'hormonothérapie, la compliance constitue un défi majeur et un problème multidimensionnel. Une meilleure compréhension des raisons de cette non-compliance aiderait à mieux identifier les patientes à risque et à développer des interventions capables d'améliorer l'adhésion à l'hormonothérapie adjuvante.C'est dans ce but que nous avons entrepris une revue de la littérature des six dernières années (Pub Med 2003-2006). [less ▲]

Detailed reference viewed: 139 (27 ULg)
Full Text
Peer Reviewed
See detailANTICORPS MONOCLONAUX ET CANCER DU SEIN: Actualités thérapeutiques
Collignon, Joëlle ULg; Gennigens, Christine ULg; Rorive, Andrée ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 279-83

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of ... [more ▼]

About 9,500 new breast cancers are diagnosed in Belgium every year. Improvement of our knowledge of altered molecular events leading to the proliferation of tumor cells has resulted in the development of targeted therapies in subgroups of cancers. One of the first validation of targeted therapy is the anti-HER-2 monoclonal antibody trastuzumab (Herceptin) in patients with overexpression of human epidermal growth factor receptor type 2 (HER2) occurring in 20 to 25% of invasive breast carcinoma. Trastuzumab binds the extracellular juxtamembrane domain and is only active in tumor with HER2 gene amplification detected by fluorescence in situ hybridization (FISH). The results from randomized trials have rapidly lead to the approvement of the drug in the metastatic and then in the adjuvant setting. Another targeted therapy, also approved in the treatment of breast cancer, is the monoclonal antibody bevacizumab with an anti-VEGF (Vascular Endothelial Growth Factor) activity. We will review the benefit of these targeted therapies in breast cancer and their role in the treatment of breast cancer. [less ▲]

Detailed reference viewed: 386 (39 ULg)
Full Text
Peer Reviewed
See detailAngiosarcome sur lymphoedeme chronique: un cas de syndrome de Stewart-Treves.
Gonne, E.; Collignon, Joëlle ULg; Kurth, William ULg et al

in Revue Médicale de Liège (2009), 64(7-8), 409-13

The Stewart-Treves Syndrome is defined as an angiosarcoma (very aggressive malignant tumor originating from endothelial cells) appearing in a specific clinical setting. This tumor develops in patients ... [more ▼]

The Stewart-Treves Syndrome is defined as an angiosarcoma (very aggressive malignant tumor originating from endothelial cells) appearing in a specific clinical setting. This tumor develops in patients suffering from chronic lymphedema of the upper limb following mastectomy and axillary lymph node dissection for breast cancer. The diagnosis relies on medical history, clinical examination and a histological assesment (biopsy or resection). This syndrome represents a rare clinical entity. Unfortunately, the prognosis is poor. A large surgical resection is the treatment of choice if the patient is a candidate for a surgical resection with a curative intent Radiotherapy is sometimes used as a palliative local treatment. Chemotherapy is only used in more advanced cases, not curable by surgery alone. [less ▲]

Detailed reference viewed: 189 (4 ULg)
Full Text
Peer Reviewed
See detailAnticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites.
Gennigens, Christine ULg; Collignon, Joëlle ULg; Jerusalem, Guy ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 264-7

For many years, chemotherapy, hormonotherapy and immunotherapy were the mainstay of cancer treatment. Recent advances in our knowledge of cell biology and particularly of cancer cell transformation ... [more ▼]

For many years, chemotherapy, hormonotherapy and immunotherapy were the mainstay of cancer treatment. Recent advances in our knowledge of cell biology and particularly of cancer cell transformation, growth and metastasis have led to the identification of specific pathways playing a role in the pathophysiology of cancer. New drugs specifically developed to control these targets are collectively named "targeted therapies". Two types of targeted therapies are available: kinase (mainly tyrosine kinase) inhibitors (suffix -nib) are small molecules binding directly to the intracellular kinase domain and acting as competitive inhibitor of ATP binding and monoclonal antibodies (suffix -mab) directed towards specific cell surface receptors or their ligands to prevent receptor activation. This paper will only review monoclonal antibodies (mabs). Thirty years after their discovery mAbs have become efficient therapeutic tools. Progress in molecular engineering as well as improved knowledge of cell signalling pathways together with a better selection of the targets turned them into valuable treatments. Several mAbs are currently licensed for the treatment of hematological or solid malignancies and many others are expected in the near future. [less ▲]

Detailed reference viewed: 87 (5 ULg)